(ALBANY, US) DELVEINSIGHT HA S LAUNCHED A NEW REPORT ON Tuberous Sclerosis Complex Pipeline
Tuberous Sclerosis Complex Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Tuberous Sclerosis Complex market. A detailed picture of the Tuberous Sclerosis Complex pipeline landscape is provided, which includes the disease overview and Tuberous Sclerosis Complex treatment guidelines.
The assessment part of the report embraces in-depth Tuberous Sclerosis Complex commercial assessment and clinical assessment of the Tuberous Sclerosis Complex pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tuberous Sclerosis Complex collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Click Here For Free Sample Page:– https://www.delveinsight.com/sample-request/tuberous-sclerosis-complex-pipeline-insight
Tuberous Sclerosis Complex of pipeline development activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Tuberous Sclerosis Complex with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Tuberous Sclerosis Complex treatment.
- Tuberous Sclerosis Complex key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Tuberous Sclerosis Complex market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Tuberous Sclerosis Complex Analytical Perspective by DelveInsight
- In-depth Tuberous Sclerosis Complex Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
- Tuberous Sclerosis Complex Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
- The Tuberous Sclerosis Complex report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Tuberous Sclerosis Complex across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Tuberous Sclerosis Complex therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Tuberous Sclerosis Complex research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Tuberous Sclerosis Complex.
KEY FACT FROM THE REPORT
- Approximately, 2.8 million people sustain TBI annually in the United States and every day 153 people in the United States die from injuries that include TBI as per Brain line organization.
- Centers for Disease Control and Prevention reported that over the span of six years (2007–2013) TBI- related ED visits have increased by 47%, hospitalization rates decreased by 2.5% and death rates decreased by 5%.
- Marek Majdan et al. estimated that about 57,000 TBI-related deaths and 1·5 million hospital discharges occurred in 2012 in Europe.
- According to data from the Overall Analysis Center of Traffic Accidents, TBI accounts for 9.3% of 1,160,000 traffic.
MAJOR KEY PLAYERS OF THE REPORT
- Vasopharm GmBH
- NeuroVive Pharmaceutical AB
- Cellvation Therapeutics
NAME OF DRUGS COVERED IN THE REPORT
- Ronopterin (VAS203)
1. Report Introduction
2. Tuberous Sclerosis Complex
2.3. Tuberous Sclerosis Complex Symptoms
2.6. Tuberous Sclerosis Complex Diagnosis
2.6.1. Diagnostic Guidelines
3. Tuberous Sclerosis Complex Current Treatment Patterns
3.1. Tuberous Sclerosis Complex Treatment Guidelines
4. Tuberous Sclerosis Complex – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Tuberous Sclerosis Complex companies collaborations, Licensing, Acquisition -Deal Value Trends
188.8.131.52. Assessment Summary
4.1.2. Tuberous Sclerosis Complex Collaboration Deals
184.108.40.206. Company-Company Collaborations (Licensing / Partnering) Analysis
220.127.116.11. Company-University Collaborations (Licensing / Partnering) Analysis
18.104.22.168. Tuberous Sclerosis Complex Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
22.214.171.124. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
126.96.36.199. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
188.8.131.52. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
184.108.40.206. Assessment by Stage and MOA
5.1.6. Assessment by Target
220.127.116.11. Assessment by Stage and Target
6. Tuberous Sclerosis Complex Late Stage Products (Phase-III)
7. Tuberous Sclerosis Complex Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Tuberous Sclerosis Complex Discontinued Products
13. Tuberous Sclerosis Complex Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
18.104.22.168. Product Overview
22.214.171.124. Mechanism of action
13.1.2. Research and Development
126.96.36.199. Clinical Studies
13.1.3. Product Development Activities
188.8.131.52. Patent Detail
13.1.4. Tabulated Product Summary
184.108.40.206. General Description Table
14. Tuberous Sclerosis Complex Key Companies
15. Tuberous Sclerosis Complex Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Tuberous Sclerosis Complex Unmet Needs
18. Tuberous Sclerosis Complex Future Perspectives
19. Tuberous Sclerosis Complex Analyst Review
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
22. About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.